Evolus Expands Management Team with Appointment of Michael Mazen Jafar as Chief Marketing Officer
Evolus, Inc. (EOLS)
Last evolus, inc. earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
us.evolis.com/investor-relations
Company Research
Source: GlobeNewswire
IRVINE, Calif., June 18, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS) (“Evolus” or the “Company”), a company dedicated to aesthetic medicine, today announced the expansion of its management team with the appointment of Michael Mazen Jafar as Chief Marketing Officer. Mr. Jafar joins Evolus from Allergan where he most recently served as Vice President, Medical Aesthetics. At Allergan Mr. Jafar led the commercial launch of Juvederm Voluma®, which has been recognized as not only one of the largest launches in the medical aesthetics category, but also the most successful, as measured by year one sales. He also led product development and marketing initiatives for the Botox® Cosmetic, Juvederm®, Kybella®, Latisse®, and Natrelle® franchises at Allergan. His most recent role at Allergan was to lead the market assessment and subsequent integration of the CoolSculpting® franchise acquired from Zeltiq. Mr. Jafar has more than a decade of product development, upstream and downstream ma
Show less
Read more
Impact Snapshot
Event Time:
EOLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EOLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EOLS alerts
High impacting Evolus, Inc. news events
Weekly update
A roundup of the hottest topics
EOLS
News
- Evolus to Report First Quarter Financial Results on May 7, 2024Business Wire
- Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra-Strength" 40U Formulation of Jeuveau® [Yahoo! Finance]Yahoo! Finance
- Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®Business Wire
- Counterfeit Botox has been found in several states. Here's what consumers should know. [CNN]CNN
- Counterfeit Botox has been found in several states. Here's what consumers should know. [CNN]CNN
EOLS
Earnings
- 3/7/24 - Miss
EOLS
Sec Filings
- 4/3/24 - Form 8-K
- 3/29/24 - Form 4
- 3/21/24 - Form 4
- EOLS's page on the SEC website